- Home
- ANVS vs BAFN Comparison
ANVS vs BAFN Comparison
Compare ANVS & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- BAFN
- Stock Information
- Founded
- ANVS 2008
- BAFN 1999
- Country
- ANVS United States
- BAFN United States
- Employees
- ANVS N/A
- BAFN N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- BAFN Savings Institutions
- Sector
- ANVS Health Care
- BAFN Finance
- Exchange
- ANVS Nasdaq
- BAFN Nasdaq
- Market Cap
- ANVS 54.6M
- BAFN 65.2M
- IPO Year
- ANVS 2020
- BAFN N/A
- Fundamental
- Price
- ANVS $2.64
- BAFN $13.85
- Analyst Decision
- ANVS Strong Buy
- BAFN
- Analyst Count
- ANVS 5
- BAFN 0
- Target Price
- ANVS $30.25
- BAFN N/A
- AVG Volume (30 Days)
- ANVS 570.5K
- BAFN 5.5K
- Earning Date
- ANVS 08-14-2025
- BAFN 07-24-2025
- Dividend Yield
- ANVS N/A
- BAFN 2.22%
- EPS Growth
- ANVS N/A
- BAFN 116.26
- EPS
- ANVS N/A
- BAFN 2.37
- Revenue
- ANVS N/A
- BAFN $80,167,000.00
- Revenue This Year
- ANVS N/A
- BAFN N/A
- Revenue Next Year
- ANVS N/A
- BAFN N/A
- P/E Ratio
- ANVS N/A
- BAFN $5.84
- Revenue Growth
- ANVS N/A
- BAFN 2.60
- 52 Week Low
- ANVS $1.11
- BAFN $11.10
- 52 Week High
- ANVS $17.88
- BAFN $19.75
- Technical
- Relative Strength Index (RSI)
- ANVS 54.28
- BAFN 37.55
- Support Level
- ANVS $2.73
- BAFN $13.55
- Resistance Level
- ANVS $3.08
- BAFN $15.30
- Average True Range (ATR)
- ANVS 0.32
- BAFN 0.77
- MACD
- ANVS -0.06
- BAFN -0.06
- Stochastic Oscillator
- ANVS 29.41
- BAFN 23.27
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.